Equities research analysts expect Abeona Therapeutics Inc (NASDAQ:ABEO) to post $1.02 million in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Abeona Therapeutics’ earnings, with estimates ranging from $200,000.00 to $1.81 million. Abeona Therapeutics posted sales of $220,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 363.6%. The firm is expected to announce its next quarterly earnings report on Wednesday, November 21st.

According to Zacks, analysts expect that Abeona Therapeutics will report full-year sales of $6.08 million for the current financial year, with estimates ranging from $5.63 million to $6.83 million. For the next financial year, analysts forecast that the firm will post sales of $18.32 million per share, with estimates ranging from $4.23 million to $43.30 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Abeona Therapeutics.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.06). The business had revenue of $0.82 million during the quarter, compared to analysts’ expectations of $1.81 million. Abeona Therapeutics had a negative net margin of 881.74% and a negative return on equity of 23.02%.

ABEO has been the topic of a number of research reports. Zacks Investment Research raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 24th. HC Wainwright set a $30.00 price target on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research note on Monday, August 13th. Maxim Group reaffirmed a “buy” rating and issued a $35.00 price target on shares of Abeona Therapeutics in a research note on Friday, August 10th. BidaskClub downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 26th. Finally, Cantor Fitzgerald set a $36.00 price target on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the stock. Abeona Therapeutics currently has an average rating of “Buy” and a consensus price target of $28.30.

Shares of NASDAQ ABEO traded down $0.15 during mid-day trading on Thursday, reaching $14.35. The company had a trading volume of 352,500 shares, compared to its average volume of 910,020. Abeona Therapeutics has a twelve month low of $10.50 and a twelve month high of $22.75. The company has a market capitalization of $683.19 million, a PE ratio of -21.74 and a beta of 1.22.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Northern Trust Corp increased its position in Abeona Therapeutics by 1.3% during the first quarter. Northern Trust Corp now owns 304,434 shares of the biopharmaceutical company’s stock worth $4,369,000 after buying an additional 3,941 shares during the last quarter. BlackRock Inc. increased its position in Abeona Therapeutics by 0.3% during the first quarter. BlackRock Inc. now owns 1,873,472 shares of the biopharmaceutical company’s stock worth $26,884,000 after buying an additional 5,094 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in Abeona Therapeutics by 11.5% during the first quarter. Schwab Charles Investment Management Inc. now owns 62,852 shares of the biopharmaceutical company’s stock worth $902,000 after buying an additional 6,500 shares during the last quarter. Fortaleza Asset Management Inc. acquired a new position in Abeona Therapeutics during the second quarter worth $104,000. Finally, Knott David M acquired a new position in Abeona Therapeutics during the first quarter worth $101,000. 76.24% of the stock is currently owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

See Also: Average Daily Trade Volume Explained

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.